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ABSTRACT: Mitochondria play a key role in oncogenesis and
constitute one of the most important targets for cancer treatments.
Although the most effective way to deliver drugs to mitochondria is by
covalently linking them to a lipophilic cation, the in vivo delivery of free
drugs still constitutes a critical bottleneck. Herein, we report the design
of a mitochondria-targeted metal−organic framework (MOF) that
greatly increases the efficacy of a model cancer drug, reducing the
required dose to less than 1% compared to the free drug and ca. 10%
compared to the nontargeted MOF. The performance of the system is
evaluated using a holistic approach ranging from microscopy to
transcriptomics. Super-resolution microscopy of MCF-7 cells treated
with the targeted MOF system reveals important mitochondrial
morphology changes that are clearly associated with cell death as soon as 30 min after incubation. Whole transcriptome analysis
of cells indicates widespread changes in gene expression when treated with the MOF system, specifically in biological processes that
have a profound effect on cell physiology and that are related to cell death. We show how targeting MOFs toward mitochondria
represents a valuable strategy for the development of new drug delivery systems.
■ INTRODUCTION
While the survival rate for most cancers has doubled over the
past 40 years, some cancers, such as those of the pancreas,
brain, lung, and esophagus, still have very poor prognoses. To
improve cancer therapies, an enormous effort has been
directed at obtaining a better fundamental understanding of
the mechanisms of cancer growth and the differences in the
metabolism between healthy and cancer cells. In particular, it is
known that mitochondria play a key role in oncogenesis and
thus constitute promising targets for novel cancer treatments.1
Mitochondria are the energy powerhouse of cells; non-
cancerous, healthy mammalian cells normally produce their
energy by oxidative phosphorylation using the electron
transport chain in the mitochondrial matrix. Cancerous cells,
however, utilize glycolysis, even in the presence of oxygen.2
This is due in part to a reprogramming of mitochondrial
function in cancer cells that increases pyruvate dehydrogenase
kinase (PDK) activity, which limits the uptake of pyruvate at a
level necessary for oxidative phosphorylation.3
In addition to cellular metabolism, and related to novel
cancer treatments, mitochondria are involved heavily in the
regulation of cell death. Evasion of cell death is a trademark
feature of cancer4 and is a determining factor in the growth of
tumor cell populations.5 Apoptosis, part of the cell death
machinery, mostly involves proteases known as caspases
(CASP), which are only activated when cell death is triggered.
Permeabilization of the mitochondrial outer membrane
triggers the caspase cascade, making treatment strategies that
cause mitochondrial permeabilization attractive.6−8 This is
especially true given that the mitochondria of cancer cells are
structurally and functionally different than those of their
healthy cell counterparts and are more susceptible to
perturbations,9 making mitochondrial targeting a means to
also selectively target cancer cells. As such, targeting cancer
cells specifically and reverting their mitochondrial metabolism
to oxidative phosphorylation as well as activating apoptosis is
an attractive strategy in cancer treatment.
The use of nanotechnology to design drug delivery systems
(DDSs) has made significant strides in cancer therapies by
improving the pharmacokinetics and biodistribution of
therapeutic agents.10 Advances in nanoformulations allow the
delivery of drugs in their pristine form, the solubilization of
hydrophobic drugs, an increase in their half-life, and a
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reduction of their side effects and immunogenicity. Among
DDSs, functional nanoparticles are attractive candidates for
selective targeting due to the possibility of modifying their
external surfaces. Metal−organic frameworks (MOFs) in
particular have arisen in the last years as favorable candidates
for nanomedicine applications, owing to their unique proper-
ties.11−17 Indeed, among the more than 90,000 structures
reported in the Cambridge Structural Database, many MOFs
show high porosity and very large surface areas (as high as
8000 m2/g), along with a highly tunable surface chemistry and
pore size.18 In addition, the synthesis of MOFs allows fine
control over particle size and shape, which is difficult to
achieve with other systems. To date, a number of therapeutics
have been encapsulated in MOFs, including anticancer,
antibacterial, and antiviral drugs, as well as nucleic acids and
biological gases.19−24 We have previously demonstrated that it
is possible to extend the release of cargo from the MOF
framework by collapsing its porosity around the payload, either
mechanically25,26 or thermally.14 We have also demonstrated
that it is possible to easily functionalize the external surface of
MOFs to enhance their colloidal stability and immunogenecity
and improve their cellular uptake by directing them to clathrin-
or caveolae-mediated endocytic pathways.16,27,28 We have also
shown that it is possible to design MOFs to obtain clinically
relevant nanoparticulate DDSs that are able to bypass
lysosomal degradation.28 In addition, a number of studies
have shown the attachment of small molecules and peptides to
specifically target cancerous cells.29−32 Very recently, some
studies have demonstrated a high level of mitochondrial
targeting that resulted in improved efficacy of microwave-
assisted thermal33 and radio/radiodynamic therapy.34
Here, we report the design and testing of a Zr-MOF, UiO-66
(UiO = Universitetet i Oslo), loaded with the cancer drug
dichloroacetate (DCA) and conjugated with triphenylphos-
phonium (TPP), which localizes to mitochondria. On the one
hand, DCA is a small molecule that inhibits PDK, reversing
cancer cell metabolism from aerobic glycolysis to oxidative
phosphorylation.35 This shift is accompanied by a down-
regulation of the abnormally high mitochondrial membrane
potential, reduced proliferation, and increased apoptosis of
cancerous cells.35,36 However, the hydrophilicity of DCA
means that it does not efficiently cross cell membranes and so
must be administered as part of a DDS to show any significant
efficiency. On the other hand, TPP is a lipophilic cation that
exhibits a single positive charge resonance stabilized over three
phenyl groups and a large hydrophobic area.37 TPP is known
to accumulate readily in mitochondria of living cells, driven by
the mitochondrial membrane potential.38−40 We have
combined the design of the DDS and in vitro experiments
with super-resolution microscopy in order to detect mitochon-
drial morphological changes associated with autophagy and cell
death in unprecedented detail. We also reveal the genome-wide
changes in transcription, related to cell death and metabolism,
using a whole-transcriptome analysis of cells treated with our
system. Altogether, using this holistic approach, our obtained
data clearly indicate a profound enhancement of the
therapeutic efficacy of DCA by the NPs presented here.
■ RESULTS AND DISCUSSION
Zirconium-based MOFs such as UiO-66 are a promising
option for drug delivery, given the low toxicity of its
components17 and large porosity (SBET = 1200 m
2 g−1, Vp =
0.5 cm3 g−1). The pristine structure of this MOF consists of Zr-
oxo clusters linked together by benzene dicarboxylate (BDC)
units to give the overall composition [Zr6O4(OH)4(BDC)6]n.
The stability of UiO-66 in water and in vivo environments is
also critical.41,42 We have shown in the past that UiO-66
generally shows good stability in water but it is quickly
degraded in the presence of phosphate salts (e.g., PBS),
although in growth media the stability is enhanced due to the
formation of a protein corona around the particles.17
Moreover, the specific use of DCA as a defect-inducing
modulator is also known to enhance aqueous colloidal
stability.43 To find a UiO-66 system with optimal mitochon-
drial targeting properties, we first synthesized three materials
using DCA as a modulator, which is trapped in significant
quantities at defect sites and the particle outer surfaces.30 We
named the materials DCAx-UiO-66, where x is the molar
equivalent of DCA relative to the linker in the initial reaction
conditions. Second, we attached 4-carboxybutyltriphenylphos-
phonium (TPP) postsynthetically to their external surface; we
named these materials TPP@(DCAx-UiO-66). Third, we
synthesized a separate UiO-66 sample with both DCA and
TPP as modulators, hence incorporating them during the
synthesis; we called this sample DCA5-TPP5-UiO-66. Figure
S1 shows the powder X-ray diffraction (PXRD) patterns for
the samples compared with the pattern predicted from the
single crystal structure, confirming the crystallinity of UiO-66
irrespective of whether TPP is incorporated during the
synthesis procedure or afterward. Table 1 shows the particle
sizes of the materials determined from SEM (Figure S2), the
colloidal analysis obtained from dynamic light scattering
(DLS) in water as well as the DCA and TPP loadings,
calculated by inductively coupled plasma optical emission
spectroscopy (ICP-OES); Figures S3 and S4 show the 1H
NMR spectra and TGA profiles. Particle sizes as determined
from SEM range from 81 to 139 nm for DCA10-UiO-66 and
DCA2.5-UiO-66, respectively, and are within the correct size
range for cellular uptake. DCA loadings range from 1.2 to 15.5
wt %, whereas TPP loadings range between 2.3 and 15.0 wt %.
Table 1. Characterization of the UiO-66-Based Drug Delivery System Particlesa
MOF particle sizeb (nm) effective diameterc (nm) PdI Z-potential (mV) DCA loading (wt %) TPP loading (wt %)
DCA10-UiO-66 81 ± 27 257 ± 1 0.17 35.4 15.5 0
DCA5-UiO-66 115 ± 48 308 ± 1 0.17 35.3 10.0 0
DCA2.5-UiO-66 139 ± 51 348 ± 4 0.21 35.5 6.1 0
DCA5-TPP5-UiO-66 131 ± 51 660 ± 26 0.51 42.2 13.0 2.3
TPP@(DCA10-UiO-66) 81 ± 27 302 ± 2 0.28 9.3 2.2 14.6
TPP@(DCA5-UiO-66) 115 ± 48 394 ± 6 0.35 12.9 1.2 7.0
TPP@(DCA2.5-UiO-66) 139 ± 51 471 ± 10 0.35 10.0 1.5 15.0
aParticle size, polydispersity (PdI), Z-potential, and DCA and TPP loadings (by ICP-OES) of the different samples. bMeasured by SEMerrors
represent the standard deviation of 100 particles. cMeasured by DLS in water.
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Unsurprisingly, TPP loadings were much higher when added
postsynthetically but the DCA loading was reduced, probably
due to additional steps in the overall synthesis. Figures S5 and
S6 show the FTIR spectra, and Figure S7 shows the N2
adsorption isotherms at 77 K.
In addition to particle size, colloidal stability is critical for
intracellular delivery applications. DCA10-UiO-66, DCA5-UiO-
66, and DCA2.5-UiO-66 have hydrodynamic diameters of 257,
308, and 348 nm in water, respectively, with polydispersity
(PdI) values ranging from 0.17 to 0.21 (Table 1). Also, the
addition of TPP postsynthetically (i.e., TPP@(DCAx-UiO-66)
samples) shows a slight increase (18−23%) in hydrodynamic
diameter compared to pristine DCAx-UiO-66 samples, with
PdI values ranging from 0.28 to 0.35. The only exception is
TPP@(DCA2.5-UiO-66), with an increment in hydrodynamic
diameter of 35%. Even though the hydrodynamic diameters for
all of the particles increase compared to SEM, they remain
within the size range that cells can take up by endocytosis,
while still displaying good colloidal stability in pure water.
DCAx-UiO-66 samples show similar z-potential values, at
around 35.4 mV, whereas the postsynthetic addition of TPP
decreases them to 7.9−15.1 mV (Table 1). This, however,
does not affect the colloidal stability of the particles, as shown
by PdI values below 0.36. The only exception here is DCA5-
TPP5-UiO-66, which, despite the high z-potential of 42.2 mV,
has lower colloidal stability, with a PdI of 0.51. It is notable
that postsynthetic loading of TPP gives much higher
incorporation (7−15% w/w) than direct inclusion of TPP in
MOF synthesis but also leads to a significant loss of DCA
cargo, suggesting detachment under these conditions. In our
postsynthetic modification, reduction of the zeta potential can
only be related to changes in the external surface chemistry, for
example, related to the loss of DCA and linker molecules. Zeta
potentials in MOFs have proven to be very difficult to
interpret, as there is a large number of factors that affect them
due to their porous and coordination nature. In particular, the
bulk chemistry greatly affects the external surface chemistry
and is dependent on factors such as the number of defects and
the constituent molecules forming the porosity. In the past, we
have observed large variations of the zeta potential in UiO-66
samples to similar values to the ones we observed here,
corroborating our observations.40
To investigate the cytotoxicity of the different materials, we
first ran an MTS assay for MCF-7 cells, analyzing it against
both the DDS and DCA concentrations to determine whether
the observed toxicity is due to DCA alone or other properties
inherent to the DDS (Figure 1a). When plotted against DDS
concentration, DCA10-UiO-66 and DCA5-UiO-66 have a
comparable effect on MCF-7 cells, decreasing viability to ca.
67% at 1 mg/mL, whereas DCA2.5-UiO-66 and DCA5-TPP5-
UiO-66 have a more pronounced effect with 48 and 36%
viability, respectively. When plotted against DCA concen-
tration, however, the different samples have different effects on
cell viability, indicating that toxicity is not solely dependent on
DCA concentration. Factors such as particle size and surface
chemistry have been shown to play a role in determining the
cellular uptake efficiency and endocytosis pathways that
nanoparticles use to enter cells.28,44 Since the different samples
have different physicochemical properties and because of the
low loading of TPP (2.3% w/w) by direct incorporation into
synthesis, it is difficult to isolate the effect of TPP as a targeting
functionality. Direct incorporation may also result in local-
ization of TPP throughout the porosity of the MOF, and not
solely at the particle external surface, further reducing any
targeting effect.
To control for the effect of particle size and isolate the effect
of TPP as a targeting agent, we then investigated the
cytotoxicity of the postsynthetically modified samples, again,
as a function of DDS and DCA concentration (Figure 1b).
Looking at the cell viability reduction, with values ranging from
35 to 23% at 1 mg/mL (Figure 1b, top), the addition of TPP
to the external surface dramatically increases the cytotoxicity of
the materials by mitochondrial targeting. When plotted against
equivalent DCA concentration, the effect is even more
important, where the cell viability was dramatically reduced
even at low concentrations of DCA (Figure 1b, bottom).
Importantly, in TPP samples, we required a ca. 10-fold lower
concentration of DCA, compared to nontargeted DCAx-UiO-
66, to achieve the same reduction in viability. To validate the
hypothesis of the synergistic effect of TPP, DCA, and UiO-66,
Figure S7 shows the cytotoxicity of the DCA drug alone, TPP
alone, DCA+TPP, naked UiO-66, and UiO-66 transporting
TPP (i.e., TPP@MOF). The results show that the individual
molecules and the TPP@MOF were not toxic up to
concentrations of 1 mg/mL, confirming previous examples in
the literature.45−47 All of this proves that the increase in
toxicity is due to the drug delivery vehicle targeting to
mitochondria.
We investigated further the mitochondrial targeting abilities
of TPP@(DCA5-UiO-66) and DCA5-TPP5-UiO-66; we
included DCA5-UiO-66 as a nontargeted control. In order to
verify the structural information and the homogeneity of the
loaded MOFs, we ran transmission electron microscopy
(TEM) and X-ray photoelectron spectra (XPS) measurements
on these three samples. Figure S8 shows the TEM images,
confirming the sizes of the particles obtained from SEM; Table
S1 shows the external surface composition (atomic %) for the
three samples, DCA5-UiO-66, TPP@(DCA5-UiO-66), and
DCA5-TPP5-UiO-66, and Figures S9 and S10 show a detailed
analysis of the C 1s, O 1s, Zr 3d, P 2p, and Cl 2p regions. All
samples contain C, O, and Zr coming preferentially from the
MOF network, while P is detected only for samples containing
TPP and Cl is detected from DCA. These results confirm the
successful incorporation of TPP and DCA in the UiO-66
formulation. A closer look at these values shows that the Cl
percentage is slightly larger for sample DCA5-UiO-66
compared to DCA5-TPP5-UiO-66 (2.5 at % vs 2.1 at %), in
agreement with ICP-OES analysis. DCA5-TPP5-UiO-66 also
shows a certain amount of P (0.1 at %), thus confirming the
successful incorporation of TPP in the formulation. Interest-
ingly, the postsynthesis modification of DCA5-UiO-66 with
TPP gives rise to important changes. The percentage of P
increases to 0.3 at %, while the amount of Cl goes down to 0.5
at %. This observation suggests that TPP is mainly located at
the MOF external surface, while DCA either remains in the
inner porosity (not detectable by XPS) or it is detached from
the structure after TPP incorporation. Another important
finding after TPP incorporation is the significant decrease in
the amount of C and the increase in the amount of Zr and O.
These observations could be associated with changes in the
surface structure during the incorporation of the TPP targeting
unit. These changes can be more clearly appreciated in the O
1s region (Figure S9).
Figure 1c shows the time-dependent MTS viability in order
to determine the kinetics of toxicity of the three MOFs on
MCF-7 cells as a function of DDS and DCA concentration. For
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the two materials containing TPP, we observe toxicity as early
as 4 h. At a DDS concentration of 1 mg/mL, viability decreases
to 78 and 66% for DCA5-TPP5-UiO-66 and TPP@(DCA5-
UiO-66), respectively, decreasing further as time progresses
but stabilizing between 8 and 48 h down to values of ca. 60−
50%. At 72 h, viability reduces further down to 36 and 12% for
both MOFs at 1 mg/mL concentration. DCA5-UiO-66, on the
other hand, remains nontoxic up to 48 h, showing only slight
toxicity after 72 h at the highest concentration of 1 mg/mL
(viability ca. 63%). When plotted as a function of DCA
concentration, it is clear that TPP@(DCA5-UiO-66), which
has the lowest levels of DCA loading and TPP present only on
the external surface, is the most toxic material, causing a sharp
decrease in cell viability after as soon as 4 h of incubation.
Interestingly, when comparing the toxicity of DCA5-TPP5-
UiO-66 and DCA5-UiO-66 based on DCA concentration, they
show similar performance for times below 72 h. At 72 h,
DCA5-TPP5-UiO-66 seems to be more active than DCA5-UiO-
Figure 1. MTS viability assay of MCF-7 cells after incubation with different systems. (a) Cell viability as a function of DDS (top) and equivalent
DCA concentration (bottom) after incubation for 72 h with different DCA-loaded DDSs. (b) Cell viability as a function of DDS (top) and
equivalent DCA concentration (bottom) after incubation for 72 h with DCAx-UiO-66 and TPP@(DCAx-UiO-66). (c) Cell viability as a function
of DDS (top) and equivalent DCA concentration (bottom) after incubation for 4−72 h with DCA5-UiO-66, TPP@(DCA5-UiO-66), and DCA5-
TPP5-UiO-66. Error barssometimes smaller than the symbol sizesrepresent the standard error of the mean of five replicate measurements.
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66. Whereas it is clear that the addition of TPP to the external
surface dramatically increases the efficacy of the UiO-66-based
DDS, its addition during the UiO-66 synthesis does not show
the same benefits. This is probably because TPP loading is
much lower, and it may be integrated throughout the MOF
matrix and therefore cannot target the particles to the
mitochondriashowing only a beneficial effect at 72 h,
perhaps due to the partial degradation and exposure of TPP
to the media. This observation of the TPP located on the
external surface area was confirmed by XPS, as described
above.
To confirm that TPP is directing the DDS to the
mitochondria, we first tracked the particles in vitro, imaging
them with a modified fluorescent pyrene group on the TPP
(fTPP), creating fTPP@(DCA5-UiO-66). Figure 2a shows the
confocal images of MCF-7 cells after 2 h of incubation with
fTPP@(DCA5-UiO-66). Mitochondria are represented in red,
and nuclei, in blue. In the merged images, we observe some
colocalization between fTPP@(DCA5-UiO-66) and RFP-
Figure 2. Microscopy imaging of MCF-7 cells. (a) Confocal microscopy images of cells incubated for 2 h with fTPP@(DCA5-UiO-66). (b) SIM
images of cells incubated for 30 min (left) and 8 h (right) with cal-TPP@(DCA5-UiO-66). fTPP and calcein are shown in green, mitochondria
stained with RFP are shown in red, and nuclei stained with DRAQ-5 are shown in blue. White arrows in confocal microscopy show overlap
between red and green signals.
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labeled mitochondria, as illustrated by the yellow color (shown
by white arrows). Additionally, most of the nonoverlapping
signal originating from fTPP@(DCA5-UiO-66) is heavily
concentrated around the mitochondria. This suggests that
the DDS is being targeted without necessarily being completely
taken up by mitochondria, possibly due to the size of the DDS
being too large for mitochondrial uptake. Given the observed
cytotoxic effect, mitochondrial uptake might not be necessary
to observe an increase in the efficacy of DCA. The mere
accumulation of particles near the mitochondria may cause
high local concentrations of toxic drug.
To better visualize the internalization of the MOF and to
better determine the existence of colocalization, we imaged the
cells using structured illumination microscopy (SIM). Since
the SIM microscope is incompatible with UV lasers, we could
not use fTPP to track our system, so we loaded the MOF with
the fluorescent molecule calcein instead. We named the
resulting MOF cal-TPP@(DCA5-UiO-66). Figure 2b shows
three-color images of cells in the presence of cal-TPP@(DCA5-
UiO-66) after 30 min and 8 h incubation. These images show
that the DDS is taken up by cells, as early as 30 min after
incubation, shown by the fact that the red-colored mitochon-
dria and green spots of MOF particles are in focus in the same
plane. After 8 h, cells take up a considerably larger amount of
MOF. In terms of colocalization with the DDS, it is difficult to
decipher from the images whether the MOF is distributed
close to mitochondria or not. This is because mitochondria are
large organelles that occupy up to 25% of the cytoplasm.
However, some interesting morphological changes, which can
be indicative of cellular health,48 are apparent. Whereas healthy
cells are expected to have elongated mitochondria that form
reticular networks, for cells treated with cal-TPP@(DCA5-
UiO-66), most mitochondria have a balloon-shaped morphol-
ogy and are notably shorter in length.
To probe the effect of the targeted DDS on mitochondrial
morphology further, we incubated MCF-7 cells with both
targeted and nontargeted MOFs loaded with calcein. We called
this new sample cal@(DCA5-UiO-66). Figure 3a shows the
SIM images of untreated and incubated cells after 8 h. In the
case of untreated cells, mitochondria are elongated and form
reticular networks, as expected (Figure 3a, left). On the other
hand, cells incubated with cal-TPP@(DCA5-UiO-66) have
Figure 3. SIM imaging of MCF-7 cells. (a) Images of untreated cells and cells treated with cal@(DCA5-UiO-66) and cal-TPP@(DCA5-UiO-66)
for 8 h; mitochondria are colored in red, MOFs in green, and nuclei in blue; white arrows indicate stringy mitochondria. (b) Images showing a
shape analysis of mitochondria using Cell Profiler software. Top row, untreated cell; bottom row, cell after 8 h of incubation with cal-TPP@(DCA5-
UiO-66). (c) The effects of different treatments on the eccentricity of mitochondria. Results show the average eccentricity of at least 200
mitochondria. Error bars represent the standard error of the mean. Statistical significance was assessed using one-way ANOVA followed by Tukey’s
multiple comparisons test.
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short, balloon-shaped mitochondria (Figure 3a, right). For
cells incubated with cal@(DCA5-UiO-66), while mitochondria
show some fragmentation, the effect is less severe than with
cal-TPP@(DCA5-UiO-66) and they still remain partially
stringy and reticular, as shown by the white arrows (Figure
3a, center). Importantly, mitochondrial morphology is very
dynamic by nature; depending on cellular requirements, they
are recycled in a dynamic equilibrium between opposing
processes of fission and fusion.49 Fusion produces extended
interconnected mitochondria that form reticular networks,
while fission produces shorter, balloon-shaped, fragmented
mitochondria. Fission is required to control cell quality by
replacing damaged mitochondria and also facilitates apoptosis
during high levels of cellular stress.50 These morphological
dynamics, as well as the spatial localization of mitochondria
inside the cell, are heavily linked to mitochondrial and cellular
function, with a good balance of fission and fusion required to
maintain general cellular functionality. Kamogashira et al., for
example, have demonstrated a fundamental interdependence
between mitochondrial metabolic activity and its network
structure.50 The fact that fragmentation of mitochondria
increases upon exposure to the targeted DDS indicates an
imbalance between fission and fusion (fission > fusion). Some
studies50,51 have demonstrated a direct link between
mitochondrial fission and mitochondrial degradation through
mitophagya mechanism by which impaired or damaged
mitochondria are encapsulated in autophagosomes that then
fuse with lysosomes where they are degraded. Interestingly,
fragmentation of mitochondriaindicating mitochondrial
damageis observed as early as 30 min after incubation
with the targeted DDS studied here (Figure 2b).
To quantify mitochondrial fragmentation, we assessed the
eccentricity of each mitochondrion and assigned to it a value
between 0 and 1, with the eccentricity of a circle being 0 and
that of an ellipse that is not a circle greater than 0 and less than
1. Figure 3b shows representative images of the original SIM as
well as of mitochondria objects identified by the Cell Profiler
pipeline; Figure 3c shows the quantification of the average
eccentricity value for untreated cells, cells treated with cal-
TPP@(DCA5-UiO-66) for 30 min and 8 h, and cells treated
with cal@(DCA5-UiO-66) for 8 h. The value for each
treatment represents the average of at least 200 mitochondria.
As expected, healthy cells have the most eccentric mitochon-
dria (0.819 ± 0.010). The larger error bars are indicative of a
wide distribution of eccentricity, which is consistent with the
fact that mitochondria in healthy cells have a dynamic balance
between fission and fusion. Cells treated with cal@(DCA5-
UiO-66) for 8 h have an average eccentricity of 0.793 ± 0.005,
which is not significantly different than the untreated control.
For cells treated with cal-TPP@(DCA5-UiO-66), the eccen-
tricity of the mitochondria is significantly reduced to 0.768 ±
0.004 after 8 h (p = 0.0002), indicating that the TPP-
containing DDS has an effect on mitochondrial morphology.
Interestingly, treatment with cal-TPP@(DCA5-UiO-66) for
only 30 min also leads to a statistically significant change in
mitochondrial eccentricity compared to untreated cells (0.786
± 0.005; p = 0.0267), demonstrating that the system has a very
rapid effect on cells. Treatment with the targeted DDS,
therefore, seems to reduce mitochondrial fusion, leading to
smaller mitochondrial entities, with a large number of small
clusters present in the mitochondrial network attributable to
the formation of autophagosomes.
To determine whether TPP@(DCA5-UiO-66) is more toxic
than DCA5-UiO-66 due to a difference in cellular uptake
mechanism, we studied the uptake pathway, using pharmaco-
logical inhibitors, by which MCF-7 cells take up these two
MOFs. The intracellular fate of particles is dependent on the
endocytosis pathway they go through, with particles taken up
through clathrin-mediated endocytosis typically ending up in
lysosomes where they are degraded along with their drug
cargo, whereas particles going through caveolae-mediated
endocytosis can sometimes be released into the cytosol and
avoid lysosomal degradation.28,44 Figure 4a shows MCF-7
cells’ internal fluorescence after incubation with the two MOFs
in the presence of different endocytic inhibitors. To determine
if the differences were statistically significant, we compared
every value to the control at 37 °C using ANOVA followed by
Dunnett’s test to adjust for multiple comparisons. When
incubated at 4 °C, cellular uptake of the MOFs was
significantly reduced by ca. 80% for cal@(DCA5-UiO-66)
and ca. 60% for cal-TPP@(DCA5-UiO-66). Cellular metabo-
lism is greatly slowed down at this temperature, which
confirms that the particles are taken up by the active
mechanism of endocytosis. When incubated with chlorproma-
zine (clathrin-mediated endocytosis), MOF uptake did not
decrease significantly for cal@(DCA5-UiO-66), whereas there
was a moderate decrease to 69% for cal-TPP@(DCA5-UiO-
66). When incubated with hypertonic sucrose, particle uptake
decreased significantly to 28 and 40% for cal@(DCA5-UiO-66)
and cal-TPP@(DCA5-UiO-66), respectively. Although sucrose
is a known inhibitor of clathrin-mediated endocytosis, there is
evidence suggesting that it is nonspecific, which might explain
why we observed a much larger degree of inhibition when cells
were incubated with sucrose as compared to chlorpromazine.
Inhibition with nystatin (caveolae-mediated endocytosis)
showed no statistically significant decrease in intracellular
fluorescence with respect to the controls for both DDSs.
Rottlerin (macropinocytosis) significantly decreased the
uptake of cal@(DCA5-UiO-66) to 56%, whereas it did not
affect the uptake of cal-TPP@(DCA5-UiO-66). These results
suggest that cal@(DCA5-UiO-66) is internalized mostly by
clathrin- and caveolae- independent endocytosis, whereas cal-
TPP@(DCA5-UiO-66) is internalized mostly by clathrin-
dependent endocytosis. The literature offers conflicting data
about the selection of endocytic pathways for charged particles.
However, studies on HeLa cells using charged NPs support
clathrin-mediated endocytosis for positively charged particles,52
which might explain why adding TPP to the surface of the
MOF leads to this internalization route. With regard to the
final intracellular fate of the particles, we have previously
shown that particles taken up by clathrin-dependent
endocytosis end up being degraded in lysosomes along with
their cargo, voiding their therapeutic effect.28,44 However,
TPP@(DCA5-UiO-66) is clearly able to reach its intended
target despite being taken up by clathrin-mediated endocytosis,
as demonstrated by its toxicity to MCF-7 cells and the imaging
studies. This could be due to the ability of positively charged
TPP to act as a proton sponge and promote endosomal escape
and the subsequent delivery of cargo into the cytosol.
At this point, we tested the hypothesis that the materials
cause cell death by apoptosis. Dysregulation of apoptosis is a
hallmark feature of most cancers, and triggering it is, therefore,
an attractive target for the design of cancer treatments. A
family of proteases called caspases are heavily involved in the
apoptotic process. We measured the activity of caspase-3/7,
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caspase-8, and caspase-9 after incubation with 0.5 and 1.0 mg/
mL of MOF for 4 and 8 h; Figure 4b shows the fold-change in
caspase activity compared to untreated cells. At a concen-
tration of 0.5 mg/mL and as early as within 4 h, there is an
increase in caspase-7 and caspase-8 activities for all of the TPP-
containing materials, followed by a return to baseline at 8 h.
DCA5-UiO-66, which does not contain TPP, shows no
increase in caspase-7 and caspase-8 activities at both 4 and 8
h. There is virtually no increase in caspase-9 activity for all four
materials at 4 and 8 h, with only DCA5-TPP5-UiO-66 showing
a slight increase in activity after 8 h. At a higher concentration
of 1 mg/mL, even TPP-absent DCA5-UiO-66 causes an
increase in caspase-7 and caspase-8 activities. It is thought that
chemotherapy typically activates caspase-9 by engaging
cytochrome C and APAF-1 at the mitochondrial membrane,
which then activates the executioner caspases 3/7. However,
our results suggest an important role for caspase-8 and not for
caspase-9. This has also been seen in several studies in which
the roles of caspase-8 and caspase-9, as well as the temporal
and hierarchical order of the caspase events, have been
questioned. For instance, Ferreira et al. demonstrated the
existence of a drug-inducible apoptosis pathway in which the
activation of caspase-8 but not caspase-9 forms the apical step
from which mitochondria-dependent apoptosis occurs.53
Wieder et al. demonstrated a death-receptor-independent
activation of caspase-8, slightly preceded by caspase-3
activation, and indicating that caspase-8 cleavage is a
downstream event of postmitochondrial caspase-3 activation.54
Pirnia et al. also demonstrated a caspase-9-independent, purely
intracellular activation of caspase-8 when treating MCF-7 cells
with mitomycin C.55
Our phenotypic cell viability assays and imaging studies
suggest that, by successful mitochondrial targeting via our
cargo system DCA, we can enhance cellular toxicity. This
cellular toxicity varies according to the differences in the design
of the targeting system. To uncover the key biophysical and
biochemical cellular pathways triggered by the different
treatments and confirm mitochondrial involvement, we
performed microarray analysis on MCF-7 cells after exposure
to the treatments for 72 h. We generated samples for
microarray analysis by treating cells independently with the
free drug DCA, or DCA incorporated into a MOF using three
different systems: DCA5-UiO-66, DCA5-TPP5-UiO-66, and
TPP@(DCA5-UiO-66). More than 10,000 genes were
detected for each comparison (Figure 5a). As expected, we
did not detect any difference in the expressed genes (DEGs)
when comparing cells treated with DCA to untreated cells (p <
0.05 or p < 0.01). This indicates that DCA at a concentration
of 0.25 mg/mL does not have any apparent effect on the
transcriptome after 72 h, i.e., that it does not alter MCF-7 gene
expression. We observed the presence of 71 DEGs (p < 0.05)
when using DCA5-UiO-66 compared to untreated cells; this
number drops down to 3 DEGs when p < 0.01. Remarkably,
both mitochondrially targeted DDSs, i.e., DCA5-TPP5-UiO-66
and TPP@(DCA5-UiO-66), induced drastic widespread
changes in gene expression profiles. DCA5-TPP5-UiO-66
Figure 4. Final fate of MOF nanoparticles in MCF-7 cells. (a) Effects of pharmacological endocytosis inhibitors on the uptake of cal@(DCA5-UiO-
66) (white bars) and cal-TPP@(DCA5-UiO-66) (red bars) by MCF-7 cells, measured by flow cytometry. (b) Caspase 7, 8, and 9 activities after
incubation of MCF-7 cells for 4 and 8 h with DCA5-UiO-66, DCA5-TPP5-UiO-66, and TPP@(DCA5-UiO-66). Samples were run in triplicate;
error bars represent the standard error of the mean. Statistical significance was assessed using one-way ANOVA followed by Dunnett’s multiple
comparisons test.
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caused significant changes in the expression level of 1519 genes
(p < 0.05), of which 821 were up-regulated and 698 were
down-regulated, and TPP@(DCA5-UiO-66) affected the
expression level of 910 genes (p < 0.05), of which 533 were
up-regulated and 377 were down-regulated. These results are
consistent with the efficacy of these drugs that we observed in
our cell viability assays where we found most toxicity in cells
treated with DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66).
Since the core component of our synthesized drug delivery
systems is DCA, which varies in its efficacy due in part to the
attached targeting agent, we performed Venn diagram analysis
at p < 0.05 to find gene targets which are common as well as
exclusive to different treatments (Figure 5b). We found that 59
gene targets were common to treatments with DCA5-UiO-66,
DCA5-TPP5-UiO-66, and TPP@(DCA5-UiO-66). These 59
genes represented 84% of the genes differentially expressed by
DCA5-UiO-66, with DCA5-TPP5-UiO-66 and TPP@(DCA5-
UiO-66) affecting numerous additional genes (1460 and 851,
respectively). This supports the results showing that the
addition of TPP to the MOF increases the efficacy of DCA on
MCF-7 cells. Figure 5d shows a gene ontology (GO) analysis
of the differentially expressed genes in MCF-7 after the
different treatments. Consistent with our phenotypic observa-
tions, analysis of the 59 common gene targets revealed the
significant enrichment of GO terms such as cell death,
apoptosis, and programmed cell death. Since the efficacy of
DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66) was much
higher than that of DCA5-UiO-66, we analyzed the gene
targets that were exclusive to DCA5-TPP5-UiO-66 or
TPP@(DCA5-UiO-66). GO analysis of the exclusive targets
revealed the significant enrichment of biological processes,
which have a more profound effect on cell physiology, such as
transcription, chromatin modification, regulation of caspase
activity, and oxidative stress, although it is difficult to pinpoint
exactly how much each component of the DDS participates in
each effect with the current experimental setup. Interestingly,
we also found significant enrichment of biological processes
such as mitochondrial transport and mitochondrial membrane
organization for the treatment with TPP@(DCA5-UiO-66),
the most toxic system to cells. Next, we explored if there is any
gene network, underlying the regulation of cell proliferation
and survival, upregulated in cells treated with drugs. By using
the STRING program,56 we performed functional protein
association network analysis with all of the genes that were
significantly upregulated in cells treated with either of the
drugs (Figure S8) and extrapolated this network with the genes
which have been reported to be functionally associated with
the genes in our list. We identified a gene network (Figure 5c),
Figure 5. Biochemical effects of different treatments on MCF-7 cells. (a) Number of differentially expressed genes between cells treated with
different conditions. (b) Venn diagram analysis of differentially expressed genes in microarrays of MCF-7 cells treated with DCA5-UiO-66, DCA5-
TPP5-UiO-66, and TPP@(DCA5-UiO-66) compared to untreated control. (c) Gene network displaying interconnected genetic targets in common
for all three treatments. (d) Significant gene ontology (GO) terms of associated biological processes from 59 differentially expressed genes (p <
0.05) in MCF-7 cells in common for all three treatments (top), treated with TPP@(DCA5-UiO-66) (middle), and treated with DCA5-TPP5-UiO-
66 (bottom).
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common to all three treatments, which is a part of the mTOR
signaling pathway, the master regulator of cell metabolism,
growth, and survival. This gene network could be built mainly
because of the gene RRAGD, a G protein which is crucial in
activating the mTOR signaling cascade, which was commonly
targeted by all three drugs. Taken together, our microarray
analysis complements our phenotypic assays and consolidates
our drug design strategy for successful targeting of mitochon-
dria.
■ OUTLOOK
We have demonstrated the successful development of a
mitochondria-targeted metal−organic framework that greatly
increases the efficacy of the anticancer agent DCA. This
targeting effect is important for novel cancer treatments due to
the key role of mitochondria in oncogenesis. In vitro viability
studies suggest that targeting the delivery system to
mitochondria greatly reduces the amount of the required
drug to less than 1% compared to the free drug and ca. 10%
compared to the nontargeted system. We have used a number
of cutting-edge techniques to elucidate the biophysical and
biochemical mechanisms of cell death. Using super-resolution
microscopy, we demonstrate that the targeted MOF localizes
around mitochondria, causing morphological changes associ-
ated with toxicity when incubated with the mitochondria-
targeted systemas soon as 30 min after treatmentthat can
be observed in unprecedented detail. Cellular uptake studies
showed no uptake through the caveolae-mediated route,
suggesting an endolysosomal route to degradation within the
cell. The observed toxicity of the targeted system is
nonetheless indicative of its ability to escape endosomes and
reach mitochondria, something that could be attributed to the
TPP acting as a proton sponge and allowing the rupture of
endosomes. We then studied the changes in gene expression
after treatment with the targeted MOF using a whole-
transcriptome analysis; we used a microarray analysis on
MCF-7 cells to examine the key biophysical and biochemical
pathways triggered by the delivery systems, where we found
widespread changes in gene expression. Key pathways affected
are biological processes having a profound effect on cell
growth, metabolism, and survival. This work allowed us to
uncover the effects of MOF-based delivery systems at the
transcriptional level, validating observations seen at the
functional level. Through this work, we show how the efficacy
of existing drugs can be dramatically improved using this
highly tunable material; our holistic approach uncovers the
potential of MOF-based DDSs and fundamentally justifies
their benefits as materials that can greatly enhance the
therapeutic efficacy of drugs. Thinking globally, we propose
this work to serve as a guideline for the exploration of future,
targeted drug delivery vehicles.
■ METHODS
Materials. ZrCl4 (99.5%) and terephthalic acid (BDC, 98%) were
purchased from Alfa Aesar (U.K.). Dichloroacetic acid (≥99%), HCl
(37%), 4-carboxybutyl triphenylphosphonium bromide (98%), 3-
(diphenylphosphino)propionic acid (97%), 1-bromopyrene (96%),
acetic acid (≥99%), dimethylformamide (DMF, 99.8%), methanol
(99.9%), and acetone (99.9%) were purchased from Sigma-Aldrich
(U.K.). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum (FBS), L-glutamine, penicillin, streptomycin, and CellLight
Mitochondria-GFP BacMam 2.0 were purchased from Invitrogen
(U.K.). The DRAQ5 stain was purchased from Abcam. Phosphate-
buffered saline (PBS), trypsin−EDTA, and Lysotracker-Deep Red
were purchased from Life Technologies (U.K.). CellTiter 96
AQueous One Solution Cell Proliferation Assay (MTS) and
Caspase-Glow 3/7, 8, and 9 Assay Systems were obtained from
Promega (U.K.). All chemicals and biochemicals used were of
analytical grade. MCF-7 (ECACC 86012803) and HEK293 (ECACC
85120602) cells were obtained from the ECACC.
Synthesis of DCA5-TPP5-UiO-66. A 10 mL portion of a DMF
solution containing BDC (149.6 mg, 0.9 mmol) and TPP (1995 mg,
4.5 mmol) was added to 10 mL of a DMF solution containing ZrCl4
(209.6 mg, 0.9 mmol) in a 25 mL glass vial. HCl (80 μL, 0.9 mmol)
and DCA (275 μL, 4.5 mmol) were added to the mixture. Next, the
vials were sealed and put in an oven at 120 °C for 24 h. The resulting
powders were collected by centrifugation (5500 rpm, 15 min) and
redispersed in 10 mL of DMF, followed by another centrifugation
cycle. This two-step washing process was repeated two more times
with DMF to remove the unreacted BDC, followed by two washes
with methanol to remove the DMF. The collected UiO-66 particles
were finally dried at room temperature under a vacuum overnight.
The amounts of DCA and TPP incorporated in the structure were
determined by ICP-OES.
Synthesis of fTPP. Synthesis of fTPP was done according to a
previously published protocol.37 1-Bromopyrene (1744 mg, 5.92
mmol) and 3-(diphenylphosphino)propionic acid (2296 mg, 8.88
mmol) were dissolved in 64 mL of toluene and were then left to reflux
overnight. The resulting yellow precipitate was hot-filtered, washed
once with methanol, and then left to dry in a rotary evaporator, giving
rise to a pale yellow solid (3.223 g, 98%).
Postsynthetic Attachment of TPP to UiO-66-DCA. A 40 mg
portion of UiO-66-DCA was dispersed in 20 mL of methanol and
sonicated for 5 min. Separately, 40 mg of either 4-carboxybutyl-TPP
or fTPP was dissolved in 20 mL of MeOH, and 0.2 mL of
triethylamine was added to the mixture. The two solutions were then
mixed and left to stir at room temperature overnight. The
nanoparticles were collected by centrifugation, washed (×2) with
methanol to wash off unattached TPP, and left to dry under a vacuum
at room temperature overnight.
Powder X-ray Diffraction (PXRD). PXRD measurements were
carried out at 298 K using a PANalytical X’Pert PRO diffractometer
(λ(Cu Kα) = 1.5418 Å) on a mounted bracket sample stage. Data
were collected over the range 5−45°.
Thermogravimetric Analysis (TGA). Measurements were
carried out using a TA Instruments Q500 Thermogravimetric
Analyzer. Measurements were collected from room temperature to
800 °C with a heating rate of 10 °C/min under an air atmosphere.
Dynamic Light Scattering. Colloidal analysis was performed by
dynamic light scattering (DLS) with a Zetasizer Nano ZS potential
analyzer equipped with NonInvasive Backscatter optics (NIBS) and a
50 mW laser at 633 nm.
ICP-OES. Zirconium, chlorine, and phosphorus quantification was
performed on a Thermo Scientific iCAP 7400 ICP-OES analyzer
against 1 and 10 ppm standards.
Nuclear Magnetic Resonance (NMR) Spectroscopy. NMR
spectra were recorded on either a Bruker AVIII 400 MHz
spectrometer or a Bruker AVI 500 MHz spectrometer and referenced
to residual solvent peaks.
UV−vis/Fluorescence Spectroscopy. UV−vis and fluorescence
spectra were recorded using a Tecan Spark Multimode Microplate
Reader.
Scanning Electron Microscopy (SEM). The powder samples
were coated with Pd for 150 s using a Polaron SC7640 sputter coater
and imaged using a Carl Zeiss Sigma Variable Pressure Analytical
SEM with Oxford Microanalysis.
Transmission Electron Microscopy (TEM). TEM measurements
were carried out on a FEI TECNAI F20 instrument with an
acceleration voltage of 200 kV. Samples were prepared by dropcasting
a sonicated methanolic suspension on a 400 mesh Cu grid.
X-ray Photoelectron Spectra (XPS). Measurements were
performed with a K-ALPHA spectrometer (Thermo Fisher Scientific,
Waltham, MA, USA) operated in the constant energy mode with
survey pass energies of 200 eV and narrow scan energies of 50 eV, to
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measure the whole energy band as well as selectively measure
particular elements. XPS spectra were acquired using Al Kα radiation
(1486.6 eV) with a twin monochromator, yielding a focused X-ray
spot at 3 mA × 12 kV. Charge compensation was attained with the
system flood gun, which provides low energy electrons and low energy
argon ions from a single source. For the reference binding energy, the
C 1s core level was used, located at 284.6 eV.
Confocal Microscopy. Measurements were carried out using a
Leica TCS SP5 confocal microscope. The microscope was equipped
with 405 diode, argon, and HeNe lasers. Leica LAS AF software was
used to analyze the images.
Super-Resolution Microscopy. Measurements were carried out
using a custom-built three-color structured illumination microscopy
(SIM) setup that has been described previously.57 The structured
illumination patterns were generated by a spatial light modulator
(SLM: SXGA-3DM, Forth Dimension Displays). A 60×/1.2 NA
water immersion lens (UPLSAPO 60XW, Olympus) focused the
structure illumination pattern onto the sample. This lens also captured
the fluorescence emission from the sample, which was imaged onto a
sCMOS camera (C11440 Hamamatsu). Laser excitation wavelengths
used were 488 nm (iBEAM-SMART-488, Toptica), 561 nm (OBIS
561, Coherent), and 640 nm (MLD 640, Cobolt), to excite the
fluorescence emission of MOF, mitochondria, and DNA, respectively.
Images were acquired using custom SIM software previously
published.57 Nine raw images were collected at each plane and
recombined using a custom implementation of the fairSIM
algorithm.58
Cell Culture. MCF-7 cells were cultured at 37 °C with 5% CO2 in
highly rich glucose (4500 mg/L) DMEM with phenol red
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 units/
mL penicillin, and 100 μg/mL streptomycin. This was named
complete DMEM (cDMEM). The cells were passaged three times a
week, whenever the cells reached 70−80% confluency.
Cytotoxicity Assays. MCF-7 cells were seed in 96-well plates at a
density of 7500 cells/well and were cultured at 37 °C with 5% CO2
for 24 h.
MTS Viability Assay. The concentration- and time-dependent
viability of cells in the presence of DCAx-UiO-66, DCA5-TPP5-UiO-
66, TPP@(DCAx-UiO-66), TPP, and DCA was investigated using the
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay
(Promega, U.K.). The day after seeding the cells, the different
MOFs and drugs were dispersed in complete medium and a range of
concentrations was prepared (0−1 mg/mL), of which 100 μL were
added to each well and incubated for 4−72 h at 37 °C with 5% CO2.
At the end of the incubation period, the treatment solutions were
removed. The cells were washed once with PBS, and then, 100 μL of
fresh growth media was added to each well. To measure the toxicity,
20 μL of MTS solution was added to each well. The plate was then
covered with aluminum foil and placed at 37 °C and 5% CO2 for 75
min. Then, 100 μL of solution from each well was transferred to a new
96-well plate. The plate was read by UV/vis spectroscopy.
Caspase Activity. Caspase 3/7, 8, and 9 activity in the presence of
DCA5-UiO-66, TPP@(DCA5-UiO-66), and DCA5-TPP5-UiO-66 was
assessed using the Caspase-Glow assay system (Promega, U.K.). Cells
were incubated in the presence of varying concentrations of MOF at 4
and 8 h. Caspase activity was then assessed according to the
manufacturer’s instructions using a TECAN Spark microplate reader.
Experiments were done in quintuplicate.
Co-Localization with Mitochondria. Cells were seeded at 100,000
cells/well in a four-well chambered cell culture cover glass and left to
grow for 24 h. They were then transfected with CellLight
Mitochondria-GFP BacMam 2.0 and left to incubate overnight. The
cells were then incubated with fTPP@(DCA5-UiO-66) for 2 h, after
which the media was removed, and the wells washed twice with PBS.
Five μM of DRAQ5 solution in media was added to the cells and left
to incubate at room temperature in the dark for 5−30 min. The cells
were then analyzed directly without further washing using a TCS SP5
inverted laser scanning microscope (Leica, Germany). An argon laser
was used to visualize GFP-stained mitochondria (excitation at 488 nm
and emission filter set at 505−555 nm). To visualize the stained
nucleus, a helium−neon laser was used (excitation at 633 nm and
emission filter set at 650−700 nm). fTPP@(DCA5-UiO-66) was
excited using a diode laser emitting at 405 nm. Images were taken
sequentially. Fluorescent images of cells were acquired as described
above. Images were then merged and converted to 8-bit RGB format
using ImageJ software.
Mitochondrial Morphology Study. Cells were seeded at 100,000
cells/well in a four-well chambered cell culture cover glass and left to
grow for 24 h. They were then transfected with CellLight
Mitochondria-GFP BacMam 2.0 and left to incubate overnight. The
cells were then incubated with cal@(DCA5-UiO-66) or cal-
TPP@(DCA5-UiO-66) for 30 min and 8 h, after which the media
was removed, and the wells washed twice with PBS. Five μM of
DRAQ5 solution in media was added to the cells and left to incubate
at room temperature in the dark for 5−30 min. The cells were then
analyzed directly without further washing using the three-color
structured illumination microscope (SIM) setup described above.
Mitochondria eccentricity was assessed using a custom-designed
pipeline for Cell Profiler.59 Briefly, the tool performed the following
actions: Extract the mitochondria channel from the central slice of the
reconstructed SIM image; apply a median filter window size of 7 to
remove elements of noise; run the “IdentifyPrimaryObjects” plugin to
extract mitochondria as objects from the image; run the
“MeasureObjectSizeShape” plugin to gather statistics on detected
objects; filter objects with an area less than 20 pixels (34 μm2); export
filtered mitochondria objects to a spreadsheet. The eccentricity
column was exported from the spreadsheet for further statistical
analysis. The one-way ANOVA test was performed using GraphPad
Prism version 7.04 for Windows to assess the statistical difference of
mitochondria eccentricity between different experimental conditions.
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Rolim-Neto, P. J.; da Silva, F. F.; Nascimento, S. C. Induction of
Cancer Cell Death by Apoptosis and Slow Release of 5-Fluoracil from
Metal-Organic Frameworks Cu-BTC. Biomed. Pharmacother. 2013,
67, 707−713.
(25) Orellana-Tavra, C.; Baxter, E. F.; Tian, T.; Bennett, T. D.;
Slater, N. K. H.; Cheetham, A. K.; Fairen-Jimenez, D. Amorphous
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c00188
J. Am. Chem. Soc. 2020, 142, 6661−6674
6672
Metal-Organic Frameworks for Drug Delivery. Chem. Commun. 2015,
51 (73), 13878−13992.
(26) Orellana-Tavra, C.; Marshall, R. J.; Baxter, E. F.; Abańades-
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